Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
In most individuals, infection with SARS-CoV-2 is either asymptomatic or produces mild illness (COVID-19) that resolves spontaneously; yet, a small proportion of patients with COVID-19 develop severe disease, require hospitalisation (often in a critical-care setting), and die.1 A dysregulated type I interferon response to SARS-CoV-2 with overproduction of proinflammatory cytokines seems to be a key pathogenic mechanism underlying progression to severe COVID-19 and death.2 Thus, controlling this excessive inflammatory response might potentially prevent disease progression.

Inhaled corticosteroids have been used for more than 30 years in the treatment of several inflammatory respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD), to control dysregulated airway inflammation, with a good efficacy and safety track record.2,3 In the context of the current pandemic, it was noted that patients with asthma and COPD appear to be under-represented among COVID-19-infected individuals seeking emergency care, and it was hypothesised that the chronic use of inhaled corticosteroids might have controlled the excessive inflammatory response induced by SARS-CoV-2 in these individuals.4 Yet, a later observational study did not support this possibility.5

In The Lancet Respiratory Medicine, Sanjay Ramakrishnan and colleagues6 explored this hypothesis in a prospective, randomised, open-label, phase 2 trial that compared treatment with 1600 µg (two puffs of 400 µg to be taken twice per day) of inhaled budesonide, a widely used inhaled corticosteroid, versus usual care in 146 adults within 7 days of the onset of mild COVID-19 symptoms.6 The primary outcome of the trial was urgent care visit, emergency department assessment, or hospitalisation.5 Results showed that, in the per-protocol analysis, this primary outcome occurred in ten (14%) participants in the usual care group and one (1%) participant in the budesonide group (difference 9%, 95% CI 0·043–0·218; p=0·004), indicating a relative risk reduction of 91% for budesonide; importantly, the number needed to treat with budesonide to reduce COVID-19 deterioration was eight patients.6 Secondary outcome results showed that clinical recovery was also significantly reduced in the budesonide group.6 Based on these observations, the authors concluded that early administration of inhaled budesonide in patients infected with SARS-CoV-2 reduced the likelihood of needing urgent medical care and enhanced clinical recovery.6

Ramakrishnan and colleagues’ study is important because it is the first to show that an easily accessible therapeutic intervention is effective to prevent COVID-19 clinical deterioration. However, the study has a potentially important limitation that needs careful consideration: it was terminated early due to “the impact of the national pandemic control measures and national prioritisation rules for clinical research trials in the UK”6 and, as a result, the number of randomised patients (n=146) was much lower than that estimated originally (n=398).6 Although
logistic conditions limiting recruitment into the study are understandable, under these circumstances it is not possible to exclude a potential type I error, so p values might not be valid. To address this potential limitation, an independent statistical assessment used bootstrap simulations of a virtual trial with the same study design, primary endpoint and duration, and concluded that the estimated power was more than 99% to reject the null hypothesis. However, this in silico exercise is only hypothesis generating, supporting, but not confirming, the working hypothesis.

In any case, and acknowledging this important limitation, the study’s results are encouraging. Inhaled budesonide is a low cost, safe (time censored), effective (number needed to treat of eight), simple, and widely available therapeutic option, which can be of great help around the world, particularly in low-income and middle-income countries, and can effectively complement the global vaccination strategy. Several potential mechanisms might underlie these clinical observations. First, inhaled corticosteroids (including budesonide) have been used successfully for decades to downregulate the excessive inflammation that characterises several chronic airway diseases such as asthma and COPD, so it is plausible that inhaled budesonide might have contributed to control the inflammatory response in early COVID-19, as systemic dexamethasone seems to do in patients with severe COVID-19. Second, in patients with asthma and COPD, inhaled corticosteroids reduce the pulmonary expression of the SARS-CoV-2 viral entry receptor, angiotensin-converting enzyme 2. Finally, some inhaled corticosteroids (including budesonide) reduce or block SARS-CoV-2 replication in vitro.

Future research will have to explore if the observations in the study by Ramakrishnan and colleagues are exclusive to budesonide, or represent a class effect of inhaled corticosteroids. In this context, it is worth mentioning that there are other ongoing randomised clinical trials using other inhaled corticosteroids or exploring the effects of budesonide in more severe (hospitalised) COVID-19 patients. Likewise, the observation that clinical recovery was accelerated in patients treated with budesonide might suggest that it can prevent or reduce COVID-19 sequelae, but this also requires specific research.

A final lesson from this study is the importance of doing well designed randomised clinical trials during a pandemic situation. Under these tragic circumstances, compassionate care is understandable but unable to produce the scientific evidence needed to guide best patient care.

AA and RF are the leading investigators of a multicentre, randomised clinical trial supported by AstraZeneca, which is currently exploring the effects of inhaled budesonide in hospitalised patients with COVID-19 pneumonia (NCT04355637).

*Alvar Agusti, Ferran Torres, Rosa Faner
agusti@clinic.cat
Catedra Salut Respiratoria, Universitat Barcelona, Spain (AA); Respiratory Institute, Hospital Clinic, 08036 Barcelona, Spain (AA); Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain (AA, FT, RF); CIBER Enfermedades Respiratorias, Spain (AA, RF); Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (FT)

1 Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med 2021; 27: 28–33.
2 Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (GOLD). 2021. www.goldcopd.org (accessed March 1, 2021).
3 Global strategy for asthma management and prevention (GINA) 2020 update. 2020. https://ginasthma.org/wp-content/uploads/2020/04/ GINA-2020-full-report-_final_.wms.pdf (accessed March 1, 2021).
4 Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med 2020; 8: 436–38.
5 Schultz A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med 2020; 8: 1106–20.
6 Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 illness (STOC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med 2021; published online April 9. https://doi.org/10.1016/S2213-2600(20)30136-X
7 Emerson SS, Kittelson JM, Gillen DL. Frequentist evaluation of group sequential clinical trial designs. Stat Med 2007; 26: 5047–80.
8 Sankoh AJ. Interim analyses: an update of an FDA reviewer’s experience and perspective. Drug Inf J 1999; 33: 165–76.
9 Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet 2021; 397: 928–40.
10 The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021; 384: 663–704.
11 Peters MC, Sajuthi S, Deford P, et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med 2020; 202: 83–90.
12 Finney LJ, Glasville N, Farme H, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. J Allergy Clin Immunol 2021; 147: 510–519.
13 Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycoprotein, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig 2020; 58: 155–68.
14 Matsuyama S, Kawase M, Nao N, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. J Virol 2020; 95: e01648–20.
15 Sibila O, Albacar N, Perea L, et al. Lung function sequelae in COVID-19 patients 3 months after hospital discharge. Arch Bronconeumol 2021; published Feb 24. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993150/ (accessed March 1, 2021).